The world is about to witness what may signal an end to decades long epidemic caused by the HIV virus.
The United States Food and Drug Administration on Wednesday approved Gilead’s twice-yearly antiviral injection for preventing HIV – a milestone that the company and some experts say could help end the threats posed by the virus.
According to report by the CNBC in the two groundbreaking clinical trials in 2024, Gilead’s injection proved to be capable of virtually eliminating new HIV infections when taken every six months.
